93 related articles for article (PubMed ID: 29661724)
1. Variation in nuclear size and PD-L2 positivity correlate with aggressive chromophobe renal cell carcinoma.
Mostafa ME; Abdelkader A; Kuroda N; Pérez-Montiel D; Banerjee A; Hes O; Iczkowski KA
Ann Diagn Pathol; 2018 Jun; 34():31-35. PubMed ID: 29661724
[TBL] [Abstract][Full Text] [Related]
2. A novel tumor grading scheme for chromophobe renal cell carcinoma: prognostic utility and comparison with Fuhrman nuclear grade.
Paner GP; Amin MB; Alvarado-Cabrero I; Young AN; Stricker HJ; Moch H; Lyles RH
Am J Surg Pathol; 2010 Sep; 34(9):1233-40. PubMed ID: 20679882
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathologic Analysis of PD-L1 and PD-L2 Expression in Renal Cell Carcinoma: Association with Oncogenic Proteins Status.
Shin SJ; Jeon YK; Kim PJ; Cho YM; Koh J; Chung DH; Go H
Ann Surg Oncol; 2016 Feb; 23(2):694-702. PubMed ID: 26464193
[TBL] [Abstract][Full Text] [Related]
4. Chromophobe renal cell carcinoma: histomorphologic characteristics and evaluation of conventional pathologic prognostic parameters in 145 cases.
Amin MB; Paner GP; Alvarado-Cabrero I; Young AN; Stricker HJ; Lyles RH; Moch H
Am J Surg Pathol; 2008 Dec; 32(12):1822-34. PubMed ID: 18813125
[TBL] [Abstract][Full Text] [Related]
5. PD-L2: A prognostic marker in chromophobe renal cell carcinoma?
Erlmeier F; Weichert W; Autenrieth M; Wiedemann M; Schrader AJ; Hartmann A; Ivanyi P; Steffens S
Med Oncol; 2017 May; 34(5):71. PubMed ID: 28353093
[TBL] [Abstract][Full Text] [Related]
6. Significance of nuclear grade and tumor size in Korean patients with chromophobe renal cell carcinoma: a comparison with conventional renal cell carcinoma.
Ku JH; Moon KC; Kwak C; Kim HH
Urol Oncol; 2011; 29(5):487-91. PubMed ID: 19767221
[TBL] [Abstract][Full Text] [Related]
7. pT1 substaging in renal cell carcinoma: validation of the 2002 TNM staging modification of malignant renal epithelial tumors.
Salama ME; Guru K; Stricker H; Peterson E; Peabody J; Menon M; Amin MB; De Peralta-Venturina M
J Urol; 2005 May; 173(5):1492-5. PubMed ID: 15821466
[TBL] [Abstract][Full Text] [Related]
8. The chromophobe tumor grading system is the preferred grading scheme for chromophobe renal cell carcinoma.
Finley DS; Shuch B; Said JW; Galliano G; Jeffries RA; Afifi AA; Castor B; Magyar C; Sadaat A; Kabbinavar FF; Belldegrun AS; Pantuck AJ
J Urol; 2011 Dec; 186(6):2168-74. PubMed ID: 22014797
[TBL] [Abstract][Full Text] [Related]
9. Distribution of subtypes of metastatic renal-cell carcinoma: correlating findings of fine-needle aspiration biopsy and surgical pathology.
Mai KT; Alhalouly T; Lamba M; Yazdi HM; Stinson WA
Diagn Cytopathol; 2003 Feb; 28(2):66-70. PubMed ID: 12561022
[TBL] [Abstract][Full Text] [Related]
10. Fuhrman grading is not appropriate for chromophobe renal cell carcinoma.
Delahunt B; Sika-Paotonu D; Bethwaite PB; McCredie MR; Martignoni G; Eble JN; Jordan TW
Am J Surg Pathol; 2007 Jun; 31(6):957-60. PubMed ID: 17527087
[TBL] [Abstract][Full Text] [Related]
11. Grading of clear cell renal cell carcinoma should be based on nucleolar prominence.
Delahunt B; Sika-Paotonu D; Bethwaite PB; William Jordan T; Magi-Galluzzi C; Zhou M; Samaratunga H; Srigley JR
Am J Surg Pathol; 2011 Aug; 35(8):1134-9. PubMed ID: 21716085
[TBL] [Abstract][Full Text] [Related]
12. The Association Between PD-L1 Expression and the Clinical Outcomes to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma.
Shin SJ; Jeon YK; Cho YM; Lee JL; Chung DH; Park JY; Go H
Oncologist; 2015 Nov; 20(11):1253-60. PubMed ID: 26424759
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Impact of PD-L2 Expression and Association with PD-L1 in Patients with Small-cell Lung Cancer.
Takamori S; Takada K; Azuma K; Jogo Y; Kinoshita F; Kozuma Y; Matsubara T; Haratake N; Akamine T; Toyokawa G; Hirai F; Tagawa T; Okamoto I; Nakanishi Y; Kawahara A; Akiba J; Oda Y; Maehara Y
Anticancer Res; 2018 Oct; 38(10):5903-5907. PubMed ID: 30275217
[TBL] [Abstract][Full Text] [Related]
14. Pathobiology and prognosis of chromophobe renal cell carcinoma.
Klatte T; Han KR; Said JW; Böhm M; Allhoff EP; Kabbinavar FF; Belldegrun AS; Pantuck AJ
Urol Oncol; 2008; 26(6):604-9. PubMed ID: 18367104
[TBL] [Abstract][Full Text] [Related]
15. Fine needle aspiration of chromophobe renal cell carcinoma.
Salamanca J; Alberti N; López-Ríos F; Perez-Barrios A; Martínez-González MA; de Agustín P
Acta Cytol; 2007; 51(1):9-15. PubMed ID: 17328488
[TBL] [Abstract][Full Text] [Related]
16. Chromophobe renal cell carcinoma: the impact of tumor grade on outcome.
Cheville JC; Lohse CM; Sukov WR; Thompson RH; Leibovich BC
Am J Surg Pathol; 2012 Jun; 36(6):851-6. PubMed ID: 22367296
[TBL] [Abstract][Full Text] [Related]
17. Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma.
Callea M; Albiges L; Gupta M; Cheng SC; Genega EM; Fay AP; Song J; Carvo I; Bhatt RS; Atkins MB; Hodi FS; Choueiri TK; McDermott DF; Freeman GJ; Signoretti S
Cancer Immunol Res; 2015 Oct; 3(10):1158-64. PubMed ID: 26014095
[TBL] [Abstract][Full Text] [Related]
18. [Chromophobe renal cell carcinoma: a clinicopathological study of 16 cases].
Nakaigawa N; Yao M; Kondo K; Kishida T; Noguchi K; Kubota Y; Nagashima Y; Kawano N; Inayama Y; Nozawa A
Hinyokika Kiyo; 2006 Jan; 52(1):1-6. PubMed ID: 16479980
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of extensive necrosis in renal cell carcinoma.
Collins J; Epstein JI
Hum Pathol; 2017 Aug; 66():108-114. PubMed ID: 28669641
[TBL] [Abstract][Full Text] [Related]
20. [Renal cell carcinoma: pathological prognostic factors, staging and histopathological classification of 355 cases].
Acosta-Jiménez E; Jerónimo-Guerrero D; Macías-Clavijo M; Rivera-Diez D; Hernández-Briseño L; Beltrán-Suárez E; Martínez-Olivares J; Ángeles-Garay U
Rev Med Inst Mex Seguro Soc; 2015; 53(4):454-65. PubMed ID: 26177433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
